Beyond Fusion: How Centinel Spine's New FDA Approval Reshapes Neck Surgery

WEST CHESTER, PA – October 14, 2026

For decades, the standard response to severe, multi-level cervical disc degeneration has been anterior cervical discectomy and fusion (ACDF). The logic was simple: if a joint is causing intractable pain, eliminate the joint. But eliminating motion in one part of the neck inevitably transfers mechanical stress to the adjacent segments, often leading to a cascade of subsequent surgeries. In the realm of healthcare innovation, the push has long been toward motion preservation—a shift from fusing the spine to replacing the damaged discs entirely.

Today, that shift accelerated. Centinel Spine, a commercial-stage medical technology company based in Pennsylvania, announced it has received U.S. Food and Drug Administration (FDA) approval for the two-level use of its prodisc C Nova cervical total disc replacement (TDR) device.

While a regulatory clearance might seem like standard industry procedure, this specific approval represents a critical maturation in spinal care. With the prodisc C Nova joining the previously approved prodisc C Vivo and prodisc C SK devices, Centinel Spine now offers three distinct cervical implants approved for both one- and two-level procedures. For patients and hospital systems alike, this signals the end of the "one-size-fits-all" approach to spinal hardware and the beginning of true anatomical customization.

The End of "One-Size-Fits-All" Hardware

Human anatomy is stubbornly diverse. The vertebral endplates of the cervical spine vary wildly in their concavity, height, and lordosis from one patient to the next. Historically, when surgeons were limited to a single implant design, they often had to aggressively alter the patient's native bone to make the hardware fit.

Centinel Spine's "Match-the-Disc" philosophy actively subverts this paradigm. By offering three distinct footprints, the company allows surgeons to adapt to the patient, rather than forcing the patient to adapt to the implant. The prodisc C Vivo features a domed superior endplate with unique spikes for fixation, ideal for highly concave anatomies. The prodisc C SK utilizes flat endplates with a streamlined keel. The newly approved prodisc C Nova, which has been utilized in international markets since 2009, features flat endplates with low-profile tri-keels designed for optimized positioning and immediate structural fixation.

"This is welcome news for spine surgeons and patients," said Christopher Summa, MD, Orthopedic Spine Surgeon with Sutter Health in Santa Cruz, CA. "Two-level approval expands the clinical application of the prodisc C Nova technology and provides me with another excellent prodisc option. I can now select among three distinct prodisc cervical devices, all with one-and two-level FDA approval. This optionality benefits my patients by allowing me to optimize implant fit and fixation based on anatomical variation."

The Bottom Line: Motion Preservation vs. Spinal Fusion

The strategic implications of this approval extend far beyond the operating table. The healthcare economy is increasingly burdened by the long-term costs of adjacent segment disease—the deterioration of discs above or below a spinal fusion.

Total disc replacement fundamentally alters this economic and clinical trajectory. The prodisc platform relies on its proprietary prodisc CORE technology, a ball-and-socket kinematic foundation with a fixed center of rotation. This design is engineered to maintain spinal balance, resist shear forces, and facilitate a physiological range of motion that protects the facet joints.

The clinical data backing this approach is formidable. Across more than 35 years of clinical history and over 300,000 device implantations worldwide, the prodisc technology platform reports a reoperation rate of less than one percent. Furthermore, long-term studies have demonstrated that patients receiving prodisc cervical implants require four times fewer reoperations after seven years compared to those who underwent traditional ACDF fusion procedures. In their landmark IDE Clinical Study for two-level indications, the prodisc C Vivo and SK devices demonstrated a massive 87.1 percent overall composite clinical success rate, with 93.9 percent of patients achieving a meaningful improvement in their Neck Disability Index (NDI).

"This approval represents another important advancement for our Match-the-Disc portfolio," notes Steve Murray, CEO of Centinel Spine. "With three distinct prodisc cervical devices now approved for both one- and two-level use, we continue to expand our cervical portfolio and advance our strategy of providing multiple implant designs to address differences in patient anatomy and disease advancement. The two-level approval of prodisc C Nova represents another important milestone in the continued evolution of our Match-the-Disc approach."

Navigating the Multi-Level Competitive Landscape

Centinel Spine is not operating in a vacuum. The multi-level cervical TDR market is intensely competitive, populated by industry heavyweights. Medtronic offers the Prestige LP, Highridge Medical champions the Mobi-C, and Globus Medical provides the Simplify system—all of which boast two-level contiguous FDA approvals.

However, Centinel Spine has carved out a highly defensible moat. While competitors generally offer a single implant design that surgeons must deploy regardless of specific endplate morphology, Centinel is the only player offering a tri-implant system. Furthermore, Centinel's prodisc platform remains the only total disc replacement system in the United States approved for one- and two-level use in both the cervical and lumbar spine. This dual-spine dominance provides a compelling value proposition for hospital procurement committees looking to streamline their vendor relationships while maximizing clinical optionality.

Strategic Implications for Hospital Procurement

For healthcare administrators and medical technology investors, the FDA's two-level clearance of the prodisc C Nova is a vital reimbursement catalyst. The transition from fusion to motion-sparing disc arthroplasty has occasionally been bottlenecked by insurance providers hesitant to cover multi-level procedures without explicit, device-specific FDA backing.

By securing two-level approvals across its entire cervical portfolio—having previously secured approvals for the Vivo and SK models in October 2025—Centinel Spine is effectively removing the "experimental" friction from the billing process. When surgeons have the regulatory green light to treat two contiguous diseased discs with customized arthroplasty, hospitals can confidently code and bill for these procedures, accelerating the institutional adoption of motion-preserving technologies.

Centinel Spine is set to highlight this expanded portfolio at the 2026 North American Spine Society (NASS) Annual Meeting in San Antonio, Texas. As thousands of spine specialists and hospital executives gather to evaluate the future of orthopedic hardware, the conversation will undoubtedly center on customization. The era of forcing a single piece of titanium to fit every neck is rapidly closing, replaced by a nuanced, patient-specific approach that prioritizes long-term movement over permanent immobility.